Proximagen

proximagen.com

Proximagen Group plc.

91-93 Farringdon Rd
EC1M 3LN London
United Kingdom

Phone

proximagen.com
Contact
Profile Products News

About Proximagen

Proximagen Group plc is focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system.

Read more about Proximagen

Advertisement

Revolutionize your production: real-time Raman analysis for maximum efficiency
Revolutionize your production: real-time Raman analysis for maximum efficiency
Efficient inline analysis for liquids and solids
Efficient inline analysis for liquids and solids
User-friendly software for effortless Design of Experiments (DoE)
User-friendly software for effortless Design of Experiments (DoE)

Product portfolio of Proximagen

Product portfolio

Show all

News about Proximagen

Proximagen

02-Mar-2012 | research and development

Proximagen Initiates Phase I Clinical Trial of PRX167700

Oral Vascular Adhesion Protein-1 antagonist for the treatment of inflammation in rheumatoid arthritis and psoriasis

Read news
Proximagen

25-Nov-2011 | business & finance

Proximagen and Altacor sign Collaborative Research and Development Agreement for Proximagen’s 5HT2c programme in Glaucoma

Proximagen Group plc  and Altacor Limited announced that they have signed a Collaborative Research and Development Agreement. Under the terms of the ...

Read news
Proximagen

04-Oct-2011 | business & finance

Lundbeck and Proximagen Sign Strategic Partnership Agreement

H. Lundbeck A/S and Proximagen Group plc

Read news
Proximagen

05-Aug-2010 | research and development

Proximagen signs Sale and Purchase Agreement for sabcomeline

Proximagen Group plc announced that it has signed a Sale and Purchase Agreement with BrainCells Inc. (BCI) for Proximagen’s sabcomeline programme. Under ...

Read news
Proximagen

08-Jul-2010 | science

Proximagen enters into a Collaboration Agreement with the NIH for a Phase II clinical trial on naluzotan

Proximagen Group plc announced that it has signed a Collaboration Research and Development Agreement (CRADA) with the National Institute of Neurological ...

Read news
Show more news about Proximagen

Here you will find Proximagen Group plc.

Last viewed contents

Unmasking hazardous compounds in cosmetics, skincare products and perfumes - New analytical methodology: Significant detection of hazardous compounds and their effects on cells

Unmasking hazardous compounds in cosmetics, skincare products and perfumes - New analytical methodology: Significant detection of hazardous compounds and their effects on cells

Go to page